Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Pathological or histological evidence of mesothelioma~2. ≥ 18 years of age~3. Not candidate for curative treatment (surgery or radiotherapy)~4. At least 4 weeks since major surgery~5. At least one measurable or evaluable lesion according to modified RECIST Criteria~6. ECOG Performance Status of 0-1~7. Life expectancy of at least 3 months~8. Participants of childbearing age must use effective contraception as indicated by the investigator~9. All subjects must sign written informed consent.~10. Able to operate the NovoTTF-100L System independently or with the help of a caregiver~Exclusion Criteria:~1. Patient candidate for surgery or radiotherapy with curative intent~2. Previous chemotherapy or radiation~3. Prior malignancy requiring anti-tumor treatment (apart from in-situ cervical cancer, in situ breast cancer, non-melanomatous skin cancers, or any malignancy for which treatment was received and there is no evidence of disease for at least 5 years) or concurrent malignancy~4. Significant co-morbidities within 4 weeks prior to enrollment, resulting in the following laboratory findings:~   1. Significant liver function impairment:~      * AST or ALT \> 3 times the upper limit of normal~     * Total bilirubin ≥ 1.5 times upper limit of normal~  2. Significant renal impairment (serum creatinine \> 1.7 mg/dL)~  3. Coagulopathy (as evidenced by PT or APTT \>1.5 times control in subjects not undergoing anticoagulation)~  4. Thrombocytopenia (platelet count \< 100 x 10\^3/μL)~  5. Neutropenia (absolute neutrophil count \< 1.5 x 10\^3/μL)~  6. Anemia (Hb \< 10 g/dL)~  7. Severe acute infection~5. Significant comorbidity which is expected to affect patient's prognosis or ability to receive the combined therapy:~   1. History of significant cardiovascular disease unless the disease is well controlled.~      Significant cardiac disease includes second/third degree heart block; significant ischemic heart disease; poorly controlled hypertension; congestive heart failure of the New York Heart Association (NYHA) Class II or worse (slight limitation of physical activity; comfortable at rest, but ordinary activity results in fatigue, palpitation or dyspnea)~  2. History of arrhythmia that is symptomatic or requires treatment. Patients with atrial fibrillation or flutter controlled by medication are not excluded from participation in the trial~  3. Active infection or any serious underlying medical condition that would impair the ability of the patient to receive protocol therapy~  4. History of any psychiatric condition that might impair the patient's ability to understand or comply with the requirements of the study or to provide consent~6. Untreated brain metastases. Asymptomatic, pretreated brain metastases not requiring steroids are allowed~7. Implanted pacemaker, defibrillator or other electrical medical devices~8. Known allergies to medical adhesives or hydrogel~9. Pregnant or breast feeding (all patients of childbearing potential must use effective contraception method during the entire period of the study based on the recommendation of the investigator or a gynecologist)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TTFields concomitant to pemetrexed plus cisplatin/carboplatin (Type: EXPERIMENTAL): Patients will be treated continuously with TTFields, in addition to pemetrexed plus cisplatin/carboplatin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete